Table 2.

Number of Patients Lost to Follow-up and Dead during First Year after HAART Initiation

	FH-Argentina (n=794)	HUCFF-Brazil (n=522)	FA-Chile (n=547)	GHESKIO-Haiti (n=1672)	IHSS/HE- Honduras (n=328)	INNSZ-Mexico (n=416)	IMTAvH-Peru (n=873)	Combined (n=5152)
Lost	135 (17%)	27 (5.2%)	20 (3.7%)	64 (3.8%)	2 (0.6%)	22 (5.3%)	27 (3.1%)	297 (5.8%)
Death within 3 months	8 (1.0%)	8 (1.5%)	15 (2.7%)	133 (8%)	23 (7%)	4 (1.0%)	50 (5.7%)	241 (4.7%)
Death within 6 months	11 (1.4%)	13 (2.5%)	21 (3.8%)	176 (10.5%)	25 (7.6%)	8 (1.9%)	67 (7.7%)	321 (6.2%)
Death within 12 months	17 (2.1%)	19 (3.6%)	32 (5.9%)	208 (12.4%)	33 (10.1%)	13 (3.1%)	77 (8.8%)	399 (7.7%)
Death within 12 months when baseline CD4<50 cells/μL	11 (6.9%)	4 (5.0%)	14 (9.9%)	84 (18.9%)	3 (6.1%)	4 (2.9%)	44 (16.9%)	164 (12.9%)